Baylon v. Office of the Ombudsman and Sandiganbayan
REITERATIONFacts
The Antecedents: In 1993, the Department of Health (DOH), through the National Kidney and Transplant Institute (NKTI), initiated the National Voluntary Blood Donation Program. Following a study revealing a high contamination rate in commercially sourced blood and an acute shortage due to retaliatory closures of commercial blood banks, the DOH expedited the program's implementation. This involved the procurement of Terumo blood bags, with Dr. Honorata Baylon serving as the Program Manager. The Commission on Audit (COA) later disallowed the purchase, citing a lack of public bidding and alleged overpricing, estimating a loss of P1,964,304.70. Procedural History: A complaint-affidavit was filed with the Ombudsman in 1997, alleging violations of R.A. 3019 (Anti-Graft and Corrupt Practices Act) and administrative misconduct against Dr. Baylon and other DOH officials. Initially, the Ombudsman's Evaluation and Preliminary Investigation Bureau (EPIB) recommended dismissal for insufficiency of evidence. However, an Assistant Ombudsman recommended disapproval of this resolution and the filing of charges. Subsequently, the Special Prosecutor filed an information before the Sandiganbayan. Dr. Baylon moved for reconsideration and reinvestigation. The Sandiganbayan ordered a reinvestigation, but later arraigned Dr. Baylon. The Office of the Special Prosecutor again recommended dismissal, but the Office of the Legal Counsel recommended denial of the motion for reconsideration and proceeding with the prosecution. The Ombudsman approved the latter recommendation. The Petition: Dr. Baylon filed a petition for certiorari and prohibition with the Supreme Court, assailing the Ombudsman's resolution finding probable cause and ordering her prosecution. She argued that the Ombudsman acted with grave abuse of discretion. The petition highlighted that the COA later lifted its disallowance, finding the purchase of Terumo blood bags without public bidding justifiable under the circumstances and that the prices were not excessive. Furthermore, Dr. Baylon contended that there was no undue injury to the government, as the prices were competitive and even lower than those offered to other government hospitals, and that there was no evident bad faith or gross inexcusable negligence on her part, given the urgency of the blood shortage and the fact that Terumo was an exclusive product. The petition also noted the dismissal of charges against higher-ranking officials, including the former Secretary of Health.
Issue(s)
Whether the Ombudsman acted with grave abuse of discretion amounting to lack or excess of jurisdiction in finding probable cause against Dr. Baylon and co-accused for violation of Section 3(e), R. A. No. 3019, as amended, and in ordering their prosecution before the Sandiganbayan. Whether there was undue injury to the Government in the procurement of Terumo blood bags. Whether Dr. Baylon and her co-accused acted with evident bad faith or gross inexcusable negligence in the procurement of the Terumo blood bags.
Ruling
The petition is granted. The resolution of the Ombudsman dated February 28, 2000, finding probable cause is reversed and set aside. The Sandiganbayan is ordered to dismiss forthwith Criminal Case No. 25703 against petitioner and her co-accused with costs de oficio.
Ratio Decidendi
On the issue of whether the Ombudsman acted with grave abuse of discretion: The Court finds the petition meritorious and holds that the Ombudsman committed grave abuse of discretion. While the Supreme Court generally defers to the Ombudsman's determination of probable cause, this deference does not extend to instances of grave abuse of discretion, which involves the exercise of power in an arbitrary, capricious, whimsical, or despotic manner. In this case, the Ombudsman's finding of probable cause was not supported by sufficient evidence, leading to an arbitrary action that warrants judicial intervention. The Court's review is justified when the Ombudsman's actions are so patent and gross as to amount to an evasion of a positive duty or a virtual refusal to perform a duty enjoined by law. The Ombudsman's failure to consider crucial evidence and recommendations, particularly those from its own Special Prosecutor and the COA's subsequent reversal, demonstrates this grave abuse. The Ombudsman's grave abuse of discretion is further highlighted by the fact that charges against Secretary Flavier were dropped, while charges against Dr. Baylon and her co-accused were pursued. The records do not provide a clear basis for this differential treatment, suggesting arbitrariness in the respondent Ombudsman's actions. This inconsistency reinforces the conclusion that the Ombudsman's decision to prosecute was not based on a sound and impartial assessment of the evidence. On the issue of whether there was undue injury to the Government: There was no undue injury to the Government. The records indicate that the prices of Terumo blood bags obtained by NKTI from FVA in 1994 were lower than those offered to other government hospitals during the same period. A comparative table shows that NKTI secured the blood bags at advantageous prices. Furthermore, the COA's initial finding of loss was based on a flawed comparison of prices from different years (1995 prices for a 1994 purchase). Crucially, the COA itself later reversed its disallowance, acknowledging that the purchase was justified under the circumstances and that the auditor had failed to conduct a proper canvass. This subsequent reversal by the COA significantly undermines the basis for the charge of undue injury. On the issue of whether Dr. Baylon and her co-accused acted with evident bad faith or gross inexcusable negligence: Even assuming, arguendo, that there was injury, there was no evident bad faith or gross inexcusable negligence on the part of the petitioner and her co-accused. Bad faith requires a dishonest purpose, moral obliquity, or conscious doing of a wrong, not merely poor judgment or negligence. Gross negligence involves a want of even slight care and a conscious indifference to consequences. In this case, the purchase was driven by an urgent need to address a severe blood shortage, a situation acknowledged and directed by the Secretary of Health. The NKTI acted promptly and diligently in response to a crisis, and their actions should be commended rather than punished. The circumstances, including the exclusivity of the distributor and the need for immediate procurement to prevent detriment to public service, justified the negotiated purchase and exempted it from public bidding requirements under Executive Order No. 301. The Ombudsman's failure to consider these exigent circumstances and the COA's later findings constitutes a grave abuse of discretion.
Main Doctrine
The Ombudsman committed grave abuse of discretion in finding probable cause against Dr. Baylon and co-accused for violation of Section 3(e) of R.A. No. 3019, as amended, when the evidence showed no undue injury to the government and no evident bad faith or gross inexcusable negligence on their part, especially considering the urgency of the situation and the COA's subsequent lifting of the audit disallowance.